Trial Profile
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cytarabine/daunorubicin (Primary)
- Indications Acute myeloid leukaemia; Lymphoma; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Pharmacokinetics
- Sponsors Celator Pharmaceuticals; Jazz Pharmaceuticals Inc
- 12 Mar 2018 Status changed from recruiting to withdrawn prior to enrolment.
- 25 Jul 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Dec 2016.
- 11 May 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.